Genitourinary Radiology: Page 17

USPSTF's 2016 CT colonography guidance boosts screening rates

By AuntMinnie.com staff writers

The 2016 update by the U.S. Preventive Services Task Force (USPSTF) of its CT colonography guidance boosted CT colonography screening rates by 50%, according to a study conducted by the Harvey L. Neiman Health Policy Institute and published March 19 in the American Journal of Preventive Medicine.

March 24, 2021

CT exam encounters could boost colorectal cancer screening

By Kate Madden Yee

Patients who are getting general CT exams could also be offered the opportunity for colorectal cancer screening, thus improving colon screening rates, according to a study published in the May-June issue of Current Problems in Diagnostic Radiology.

March 24, 2021

CTC is most effective way to detect advanced neoplasia

By Kate Madden Yee

CT colonography (CTC) with a polyp size threshold of ≥ 10 mm is more effective than multitarget stool DNA and fecal immunochemical testing for diagnosing advanced neoplasia, according to a study published online March 11 in the American Journal of Roentgenology.

March 11, 2021

MRI-first prostate screening could reduce death rates

By Kate Madden Yee

Performing MRI scans before biopsy on men with high prostate-specific antigen scores could reduce prostate cancer death rates by as much as 18% versus no screening, while also reducing the harms of screening, according to a March 11 study in JAMA Network Open.

March 10, 2021

Promaxo gets FDA clearance for office-based MRI scanner

By AuntMinnie.com staff writers

Medical imaging, robotics, and artificial intelligence technology firm Promaxo has received clearance from the U.S. Food and Drug Administration (FDA) for its office-based Promaxo MRI scanner.

March 7, 2021

CT-guided renal ablation is safe for treating cancer in obese patients

By Kate Madden Yee

CT-guided renal ablation is a safe and effective alternative to nephrectomy in morbidly obese patients, according to a study published February 17 in the American Journal of Roentgenology.

February 23, 2021

Short MRI exam shows promise for prostate cancer screening follow-up

By Kate Madden Yee

Researchers found that a short, biparametric MRI protocol without contrast was able to find twice as many clinically significant prostate cancers compared with prostate-specific antigen testing in a study published February 11 in JAMA Oncology.

February 10, 2021

MRI-targeted biopsy shows value in prostate cancer

By Erik L. Ridley

Multiparametric MRI-targeted biopsy for clinically significant prostate cancer can yield detection rates similar to systematic transrectal ultrasound-guided biopsy, while potentially enabling over one-third of prostate biopsies to be avoided, according to research published online February 4 in JAMA Oncology.

February 4, 2021

AI, radiomics predicts prostate cancer recurrence

By Erik L. Ridley

A diagnostic model that incorporates artificial intelligence (AI) analysis of radiomics features on multiparametric MRI can predict the likelihood of prostate cancer recurrence prior to surgical treatment, enabling preoperative risk stratification of patients, according to research published in the January issue of EBioMedicine.

January 18, 2021

Blue Earth eyes new uses for fluciclovine F-18

By AuntMinnie.com staff writers

Bracco molecular imaging subsidiary Blue Earth Diagnostics announced that the first patient has been dosed in a phase III clinical study examining the use of its Axumin (fluciclovine fluorine-18, F-18) PET radiopharmaceutical for detecting recurrent brain metastases.

January 14, 2021

Blue Earth buys therapeutic rights to rhPSMA technology

By AuntMinnie.com staff writers

Bracco molecular imaging subsidiary Blue Earth Diagnostics has acquired exclusive, worldwide rights to therapeutic applications of radiohybrid prostate-specific membrane antigen (rhPSMA) technology developed by German radiopharmaceutical firm Scintomics and the Technical University of Munich.

January 4, 2021

FDA makes history with approval of Ga-68 PSMA-11 PET

By Wayne Forrest

The U.S. Food and Drug Administration's (FDA) recent approval of a PET radiotracer that targets lesions positive for prostate-specific membrane antigen (PSMA) is not only a "quantum leap" for the diagnosis of prostate cancer in men but also sets a precedent for academic research.

December 17, 2020

Previous Page

Page 17 of 93

Next Page